INTRODUCTION
============

The main consequences of maternal HIV infection to fetal health are mother-to-child transmission (MTCT) and the potentially increased risk of adverse pregnancy outcomes. The timely diagnosis and the provision of free antiretroviral therapy (ART) reduced MTCT[@B12] in Brazil. Attention must now be paid to the potentially increased risk for preterm birth (PTB) and intrauterine fetal growth restriction (IUGR).

PTB and IUGR are the most determining factors of perinatal morbidity and mortality all over the world[@B13] ^,^ [@B33], which are also more related to neonatal complications[@B50] ^,^ [@B59], poor postnatal growth[@B05] ^,^ [@B22] ^,^ [@B23], and diseases whose consequences may extend to late adulthood[@B03], with the burden of the high cost of prolonged surveillance and intervention[@B18].

The relationship between these adverse outcomes and the intrauterine exposure to HIV and to antiretroviral treatment remains controversial and unresolved. It is unknown if PTB and IUGR result from a direct effect of the virus, from the immunosuppression, from associated co-morbidities or from non-HIV associated factors[@B04]. Antiretroviral therapy use has also been suggested as a possible risk factor[@B19] ^,^ [@B38].

The reported prevalence of PTB and IUGR in infants born to HIV-infected mothers is variable and inconsistent[@B29] ^,^ [@B46]. This may be due to several reasons, including inappropriate assessment of gestational age (GA), lack of a standardized definition and assessment of IUGR, and the absence of adjustment for confounding factors[@B04] ^,^ [@B13]. The difficulty of obtaining precise information on GA has resulted in the use of low birth weight (LBW) as a proxy for IUGR in some studies[@B46]. In many places, the same social and behavioral risk factors related to HIV-infection, preterm birth and IUGR may be shared by the same women, resulting in a high prevalence of these adverse outcomes[@B50].

In this scenario, it is necessary to know the local reality in order to face the challenge. The city of Vitória has a population of about 327,081 with a 0.856 human development index, the lowest infant mortality rate in Brazil (7.93 : 1000) with a perinatal component of 65.7%[@B56] and a 63.0% fetal death proportion[@B39]. However, as in other places, there is high income distribution disparity and limited access to high quality healthcare[@B41]. From 1997 to 2001, the prevalence rate of HIV-infection in pregnant women was 0.41%[@B41], which was similar to the mean Brazilian rate[@B52]. The 3.1% MTCT rate was also similar to the 2.7 to 8.6% prevalence rates reported for Brazil[@B38] ^,^ [@B47] ^,^ [@B52].

Most of the published Brazilian studies have focused on gestational HIV-infection prevalence and on the MTCT rate with less attention paid to PTB and IUGR prevalence and associated outcomes. Therefore, the aim of this study was to determine the prevalence of PTB and of fetal growth disturbances in a public tertiary referral maternity unit for low income, HIV-infected women who are taking ART, as well as to verify its relation to the HIV infection stage.

PATIENTS AND METHODS
====================

This is a case series observational and analytic study conducted at Cassiano Antonio Moraes University Hospital (HUCAM), a 314-bed tertiary public hospital in the city of Vitória, state of Espírito Santo, Southeastern Brazil. The HUCAM is one of the three regional referral centers for the treatment and care of HIV-infected patients, with an annual mean of 1500 deliveries.

Data were retrieved from HUCAM records for all 250 deliveries of HIV-infected pregnant women that occurred between November 2001 and May 2012. From this data, gestations that met all the following criteria were selected for study: known maternal HIV-infection diagnosis, singleton pregnancy, a minimum of 22 gestational weeks confirmed by an ultrasound examination before 22 weeks, and an adequate set of maternal and fetal biometrical data suitable for fetal growth analysis. One twin pregnancy was excluded, as were cases with missing ultrasound data or unavailable clinical records. In the studied period, one woman had two gestations and the remaining women had only one, totaling 74 gestations from 73 women for the study.

The study protocol was approved by the Institutional Review Board. As a retrospective survey of records, informed signed consent was not required, but access to patients\' records was obtained from institutional and Public Health Authorities. All women and their children received the standard obstetrical and neonatal care. Strict confidentiality was adhered to regarding any data collected throughout the study.

Data on maternal, pregnancy and neonatal characteristics including infant HIV status during pediatric follow-up were collected from medical, obstetrical, neonatal and laboratory institutional records as well as the State Health Secretariat public reports. The data were extracted in a structured form, entered and analyzed in an Excel sheet (Microsoft Office 2010, Microsoft Corporation, USA) formatted to calculate the GA and to analyze the fetal dimensions and growth.

The diagnosis of HIV infection was based on the Brazilian National AIDS Program guidelines, with the following considered as positive indicators: a positive sample by ELISA screening, with confirmation by Western blot or indirect fluorescence reaction, and HIV infection diagnosis by Rapid Tests[@B11]. An HIV infection was classified as AIDS according to the current modified Centers for Disease Control and Prevention (CDC) criteria and the Rio de Janeiro-Caracas (1992) criteria and/or a documented medical AIDS diagnosis[@B11]. Children exposed to HIV were followed and those with two positive HIV DNA polymerase chain reaction (PCR) tests were classified as HIV-infected; a child with at least one negative DNA PCR test after the age of two months or a negative HIV-antibody test after the age of 18 months was classified as uninfected[@B11]. The medication type, duration, and beginning of use were combined to describe the multiclass ART used by each woman, during each week of gestation. A medication was considered as taken if used for at least five uninterrupted weeks. The beginning of use was classified according to the critical fetal growth period as either before 16 weeks (including before pregnancy), between 16 and 28 weeks or after 28 weeks of gestation.

Maternal BMI was classified according to WHO criteria[@B58] and HIV-associated co-morbidity was ascertained according to the Rio de Janeiro-Caracas criteria[@B11].

The GA at birth was expressed in exact days of gestation, calculated from the last menstrual period if confirmed by ultrasound examination before 22 weeks, using the last menstrual period estimate in cases with a discrepancy of up to seven days; otherwise the ultrasound estimate was used[@B43] ^,^ [@B44]. In cases of fetal deaths, the GA at death was calculated by subtraction of the intrauterine retention time estimated by anatomic-pathological criteria[@B28] from the calculated GA at birth. PTB was defined as delivery at less than 37 weeks of gestation, and very PTB as less than 34 weeks of gestation. Major fetal congenital malformation includes potentially lethal abnormalities or those that will require immediate postnatal surgery[@B57].

Neonatal dimensions (birth weight (BW), birth length (BL), head (HC) and abdominal (AC) circumferences) were measured within 24 hours of birth by neonatal doctors or nurses. In fetal death cases, the autopsy dimensions were used. Low birth weight (LBW) was defined as less than 2,500 grams, macrosomia as more than 3,999 grams and normal weight as anything between these two values.

To compare the various fetal dimensions, regardless of the GA at birth, all fetal dimensions were converted to z-scores for gestational age (z/GA score), using published fetal normative reference values for weight[@B25], BL[@B17], HC[@B15], and AC[@B16], re-expressed as proportional growth curves[@B25] ^,^ [@B26] ^,^ [@B27] and adjusted for location, term of pregnancy, neonatal measurement, and population median value at 40 weeks as has been recently recommended[@B07] ^,^ [@B26] ^,^ [@B32] ^,^ [@B40]. For birth length, the fetal length was estimated by femur diaphyseal length using the Hadlock formula[@B30] and the proportional growth curve was elaborated with the Chitty fetal femur length growth curve[@B17]. For the local values, the birth weight (3458 ± 415g), length (495 ± 23mm), head (350 ± 15mm) and abdominal circumference (325 ± 20mm) values at 277 to 284 days (40 weeks) from 273 singleton (male and female), non-malformed, live births in the city of Vitória from middle and high-income women between 2008 and 2013 were taken. The reference values for fetal weight (FW) were further adjusted for maternal race, weight, height, parity and fetal gender[@B25] and BL[@B30] and HC for fetal sex only[@B48]. Each fetal dimension was categorized as small (SGA), adequate (AGA) and large (LGA) for GA, defined as having a z/GA value below, between or beyond the ±1.28 z/GA score, the usual clinical cut-off to demarcate the 10^th^ and 90^th^ percentiles. Venn diagrams were used to analyze the combining distribution of the PTB, LBW and categorized fetal growth assessments.

**Statistical analysis**. Cases with missing data for a variable were excluded from the analysis of that specific variable. The available data from excluded cases were compared with the included cases. For categorical data, frequency distributions and corresponding 95% confidence intervals (95% CI) were calculated. For continuous variables, a standard descriptive statistical analysis was performed, including the calculation of the arithmetic mean and standard deviation, median, quartiles and range as well as the distribution depicted as box-plots[@B31]. The proportions of observed growth disturbances categories (SGA, AGA, and LGA), were compared with the expected values (10%, 80%, and 10%), taking the reference value distribution as a control group[@B14]. The quantitative contrasts between groups\' proportions were analyzed by direct increment[@B24], and by chi-square test statistics with a bicaudal 0.05 significance value; the Fisher exact test was used if the expected count for a cell table was less than 5.

RESULTS
=======

**Casuistry, maternal, gestational and perinatal characteristics, and outcome**. The 74 cases studied amount to 26.6 % of HUCAM and 6.6% of all Espírito Santo State maternal HIV-infected deliveries in the studied period. Maternal demographic, clinical, obstetrical and perinatal details and outcomes are shown in [Tables 1](#t01){ref-type="table"} and [2](#t02){ref-type="table"}.

###### Sociodemographic, behavioral, and medical characteristics

                                                      Included cases                   Excluded cases   
  --------------------------------------------------- ---------------- --------------- ---------------- ------------------------------------------------
  **Demographic**                                                                                        
      Maternal age - less than 20 years               3/34 (8.8%)      1/40 (2.5%)                      18/172 (10.4%)
      Maternal age - more than 35 years               3/34 (8.8%)      7/40 (17.5%)                     13/172 (7.5%)
      Ethnicity - non-white                           28/34 (82.3%)    28/40 (70.0%)                    115/150 (76.6%)
      Instruction - illiterate or less than 5 years   9/34 (26.4%)     10/40 (25.0%)                    15/35 (42.8%)
      Instruction - 5 to 8 years                      11/34 (32.3%)    10/40 (25.0%)                    13/35 (37.1%)
      Occupation - housewife                          20/33 (60.6%)    23/40 (57.5%)                    84/105 (80.0%)[b](#TFN02){ref-type="table-fn"}
      Marital status - unmarried                      3/31 (9.6%)      8/39 (20.5%)                     14/32 (43.7%)[b](#TFN02){ref-type="table-fn"}
      Residency outside Vitoria City                  25/34 (73.5%)    27/40 (67.5%)                    90/160 (56.2%)[b](#TFN02){ref-type="table-fn"}
  **Obstetrical history**                                                                                
      Primiparity                                     10/34 (29.4%)    8/40 (20.0%)                     8/34 (23.5%)
      Multiparity - 3 or more                         10/34 (29.4%)    10/40 (25.0%)                    10/34 (29.4%)
      Previous abortion                               11/34 (32.3%)    13/40 (32.5%)                    8/34 (23.5%)
      Previous perinatal death                        4/34 (11.7%)     3/40 (7.5%)                      1/34 (2.9%)
  **Current pregnancy**                                                                                  
      Prenatal care - \< 6 attendances                7/33 (21.2%)     10/40 (25.0%)                    37/63 (58.7%)[b](#TFN02){ref-type="table-fn"}
      Prenatal care - not in HUCAM                    21/34 (61.7%)    19/40 (47.5%)                    35/61 (57.3%)
      Body mass index - \< 18.5                       3/34 (8.8%)      4/38 (10.5%)                     4/31 (12.9%)
      Body mass index - 25 \< BMI \< 30               6/34 (17.6%)     9/40 (22.5%)                     6/31 (19.3%)
      Body mass index - BMI \> 29.9                   4/34 (11.7%)     1/40 (2.5%)                      2/31 (6.4%)
      Smoking - any                                   4/34 (11.7%)     7/39 (17.9%)                     16/34 (47.0%)[b](#TFN02){ref-type="table-fn"}
      Alcohol abuse                                   2/34 (5.8%)      0/40 (0.0%)                      7/35 (20.0%)[b](#TFN02){ref-type="table-fn"}
      Illicit drug use                                2/34 (5.8%)      1/40 (2.5%)                      7/35 (20.0%)[b](#TFN02){ref-type="table-fn"}
      Maternal anemia                                 6/32 (18.7%)     5/38 (13.1%)                     10/31 (32.2%)
      Hypertension (any type)                         4/33 (12.1 %)    5/40 (12.5%)                     3/32 (9.3%)
      Urinary tract infection                         7/33 (21.2%)     6/40 (15.0%)                     5/31 (16.1%)
      Diabetes mellitus                               1/33 (3.0%)      0/40 (0.0%)                      0/34 (0.0%)
      Syphilis                                        1/33 (3.0%)      1/40 (2.5%)                      5/31 (16.1%)[b](#TFN02){ref-type="table-fn"}
      HSV infection                                   0/33 (0.0%)      2/38 (5.2%)                      1/34 (2.9%)
      HPV infection (condiloma acuminatum)            2/32 (6.2%)      3/38 (7.8%)                      3/33 (9.0%)

: number refers to absolute frequency (F) of category, number of cases with data (N) and relative frequency (%);

: *p* \< 0.05 on chi square or Fisher exact test between included versus excluded cases;

**c:** *p* \< 0.05 on chi square or Fisher exact test between HIV versus AIDS cases; non-significant contrast not flagged.

###### Labor, perinatal outcome and HIV infections details

                                                  Included cases                                                       Excluded cases   
  ----------------------------------------------- -------------------- ----------------------------------------------- ---------------- -------------------------------------------------
  **Labor and perinatal outcome**                                                                                                        
      Labour - spontaneous                        12/34 (35.2%)        13/40 (32.5%)                                                    16/34 (47.0%)
      Labour - none                               19/34 (55.8%)        26/40 (65.0%)                                                    18/34 (52.9%)
      Rupture of Membranes - spontaneous          6/33 (18.1%)         8/39 (20.5%)                                                     9/34 (26.4%)
      Caesarian delivery                          26/34 (76.4%)        37/40 (92.5%)[c](#TFN05){ref-type="table-fn"}                    109/155 (70.3%)[b](#TFN04){ref-type="table-fn"}
      Fetal sex - female                          22/34 (64.7%)        19/40 (47.5%)                                                    77/154 (50.0%)
      Gestational age - mean ± s (days)           267 ± 19             262 ± 24                                                         263 ± 25
      Gestational age - median (IQR)              271 (266 - 275)      271 (263 - 273)                                                  271 (260 - 278)
      Preterm birth - less than 37 weeks          2/34 (5.9%)          11/40 (27.5%)[c](#TFN05){ref-type="table-fn"}                    22/92 (23.9%)
      Birth weight - mean ± sd (grams)            2939 ± 715           2717 ±751                                                        2840 ± 684
      Birth weight - median (IQR) (grams)         2950 (2669 - 3339)   2893 (2519 - 3169)                                               2900 (2550 - 3280)
      Low birth weight - less than 2500 grams     5/34 (14.7%)         10/40 (25.0%)                                                    36/157 (22.9%)
      Apgar score - less than 7 in first minute   1/33 (3.0%)          1/39 (2.5%)                                                      13/150 (8.6%)
      Need for intensive neonatal care            7/32 (21.8%)         11/39 (28.2%)                                                    5/32 (15.6%)
      Major congenital anomalies                  0/34 (0.0 %)         2/40 (5.0%)                                                      0/35 (0.0%)
      ToRCH infection - syphilis                  1/74 (2.9%)          1/40 (2.5%)                                                      \-
      ToRCH infection - toxoplasmosis             0/74 (0.0%)          1/40 (2.5%)                                                      \-
      Fetal death                                 1/34 (2.9%)          1/40 (2.5%)                                                      2/172 (1.1%)
      Neonatal death                              0/34 (0.0%)          1/40 (2.5%)                                                      3/172 (1.7%)
  **HIV infection details**                                                                                                              
      HIV diagnosis prior to current pregnancy    15/34 (44.1%)        36/41 (87.8%)[c](#TFN05){ref-type="table-fn"}                    22/35 (62.8%)
      HIV status of sexual partner - positive     13/23 (56.5%)        13/27 (48.1%)                                                    12/20 (60.0%)
      Cases with AIDS defining features           \-                   40/74 (54.1%)                                                    70/119 (58.8%)
      Viral load - 1000 to 10000 copies           8/24 (33.3%)         6/39 (15.3%)                                                     6/25 (24.0%)
      Viral load - more than 10000 copies         4/24 (16.6%)         8/39 (20.5%)                                                     6/25 (24.0%)

: number refers to absolute frequency (F) of category, number of cases with data (N) and relative frequency (%);

: *p* \< 0.05 on chi square or Fisher exact test between included versus excluded cases;

: *p* \< 0.05 on chi square or Fisher exact test between HIV versus AIDS cases; non-significant contrast not flagged.

**HIV infection**. HIV infection was diagnosed before the current pregnancy in 68.9% of cases and during antenatal care in 31.1% of cases. AIDS cases amounted to 40 (54.1%) of the cases. Among cases with data, 28.8% (19/66) had a CD4 count of less than 350 cells/mm^3^ (10.6% less than 200 cells/mm^3^), and 19.0% (12/63) had higher than 10,000 viral load copies/mL. Out of 54 children with at least 18 months of postnatal follow-up, there was no MTCT of HIV; no data were available about the 20 other children.

**Perinatal outcome.**The cesarean delivery rate was 85.1%, without variation in the studied period. There was one neonatal death and two major fetal congenital malformations, all three from AIDS cases.

**Antiretroviral therapy**. According to ART use criteria (being used for at least five uninterrupted weeks of gestation), the lack of use of any ART during gestation was observed in five of the 74 cases (6.8%). Of the 69 gestations in which ART was used, 24 (34.8%) started ART prior to the current gestation, 11 (15.9%) started between one and 15 weeks, 30 (43.5%), between 16 and 28 weeks, and four (5.8%) between 29 weeks and delivery; intrapartal zidovudine was used in 95.7% cases. One-drug ART was used in six (8.7%) of the cases, two-drug therapy in one (1.4%), and a three or more drug therapy (HAART) in 62 (89.9%); 56 (90.3%) out of the 62 HAART users took a protease inhibitor, of which 19 (30.6%) took the protease inhibitor drug during the whole gestation. Therapy drug switch was observed in nine (13.0%) of the 69 cases.

**Gestational age**. The mean GA for all cases was 264 (37 weeks and 6 days) ± 22 days, but was five days lower for the AIDS cases. The overall PTB rate was 17.5% (95% CI: 0 to 38.3%) ([Table 3](#t03){ref-type="table"}), higher in AIDS cases; the very preterm birth (less than 34 weeks) rate was 10.8% without significant difference between AIDS and HIV-only cases; no post-term delivery was observed. A comparison between the included and the excluded cases regarding PTB revealed similarity, but there was a significant difference between the AIDS and HIV-only cases ([Table 2](#t02){ref-type="table"}).

###### Distributions of gestational age, absolute and z score value of fetal dimensions, and proportions of preterm births, low birth weight and small for gestational age

  Variable                                                 All cases            HIV cases            AIDS cases            
  -------------------------------------------------------- -------------------- -------------------- -------------------- -----------------------------------
  **Gestational age (days) - n**                           **74**               **34**               **40**                
      mean ± sd                                            264 ± 22             267 ± 20             262 ± 23              
      median (interquartile range)                         271 (265 - 275)      271 (266 - 277)      271 (263 - 274)       
      \<34 weeks - F (%)[a](#TFN06){ref-type="table-fn"}   8 (10.8%)            2 (5.8%)             6 (15.0%)            ns
      \<37 weeks - F (%)                                   13 (17.5%)           3 (8.8%)             10 (25.0%)           ns
  **Fetal weight (grams) - n**                             **74**               **34**               **40**                
      mean ± sd                                            2819 ± 738           2939 ± 715           2717 ±751             
      median (interquartile range)                         2915 (2595 - 3232)   2950 (2669 - 3339)   2893 (2518 - 3169)    
      z/GA score - mean ± sd                               -0.40 ± 1.37         -0.23 ± 1.49         -0.55 ± 1.26          
      \< 2500 grams                                        15 (20.2%)           5 (14.7%)            10 (25.0%)           ns
      SGA - F (%)                                          12 (16.2%)           6 (17.6%)            6 (15.0%)            ns
  **Fetal length (mm) - n**                                **73**               **33**               **40**                
      mean ± sd                                            466 ± 40             478 ± 26             456 ± 47              
      median                                               470 (460 - 485)      475 (460 - 490)      470 (444 - 485)       
      z/GA score - mean ± sd                               -0.55 ± 1.28         -0.19 ± 1.00         -0.86 ± 1.14          
      SGA - F (%)                                          14 (19.1%)           2 (6.0%)             12 (30.0%)           [\*](#TFN07){ref-type="table-fn"}
  **Head circumference (mm) -n**                           **72**               **33**               **39**                
      mean ± sd                                            335 ± 30             339 ± 21             330 ± 36              
      median                                               340 (330 - 350)      340 (335 - 350)      340 (330 - 348)       
      z/GA score - mean ± sd                               -0.28 ± 1.32         -0.20 ± 1.00         -0.35 ± 1.54          
      SGA - F (%)                                          10 (13.8%)           3 (9.0%)             7 (17.9%)            ns
  **Abdominal circumference (mm) - n**                     **63**               **30**               **33**                
      mean ± sd                                            303 ± 40             307 ± 27             300 ± 49              
      median                                               310 (295 - 330)      308 (300 - 320)      310 (290 - 330)       
      z/GA score - mean ± sd                               -0.40 ± 2.03         -0.41 ± 1.13         -0.39 ± 2.62          
      SGA - F (%)                                          11 (17.4%)           4 (13.3%)            7 (21.2%)            ns

: number refers to absolute frequency (F) of category, number of cases with data (N) and relative frequency (%).

: *p* \< 0.05 on chi square test between HIV versus AIDS cases; non-significant contrast not flagged.

**Fetal growth disturbances**. The distribution of fetal growth disturbances in all cases and according to HIV infection status (HIV-only and AIDS) is shown in [Figure 1](#f01){ref-type="fig"} and in [Table 3](#t03){ref-type="table"}. The median birth weight was 57 grams higher in HIV-only cases compared to AIDS cases. LBW was observed in 20.2% (95% CI: 11.1 to 29.5%) of cases, with a higher non-significant proportion (25.0% versus 14.7%) in AIDS than in HIV-only cases. Fetal macrosomia was observed in one HIV-only case.

![Distribution of z-score for gestational age of fetal dimensions.](0036-4665-rimtsp-57-02-0111-gf01){#f01}

The mean BW z/GA score was -0.40 ± 1.37 (all cases), -0.55 (AIDS), and -0.23 (HIV-only) cases. SGA BW was found in 16.2% (95% CI: 7.8 to 24.6%) of cases without significant difference between HIV-only and AIDS cases (17.6% versus 15.0%); among the 12 SGA birth weight three (25.0%) were preterm. LGA BW was found in 6.8% (95% CI: 1.1 to 12.5%) of cases, occurring in all but one of the HIV-only cases. LBW and SGA BW were not significantly more frequent in cases with mothers that were smokers compared to those that were non-smokers (9.1% versus 9.7% and 9.1% versus 17.7%, respectively).

The mean BL z/GA score was -0.55 ± 1.27 (all cases), -0.19 (HIV-only), and -0.86 (AIDS). The median birth length was 5 mm lower in AIDS than HIV-only cases ([Table 3](#t03){ref-type="table"}) but a SGA BL was found in 19.1% (95% CI: 10.0 to 27.8) of cases, with a higher significant rate in AIDS cases (30.0% versus 6.0%). LGA BL was found in 4.1% of cases (95% CI: 0 to 8.6%), all in HIV-only cases.

The mean head circumference z/GA score was slightly reduced with a mean of -0.28 ± 1.32 (all cases), -0.20 (HIV-only), and -0.35 (AIDS). A SGA HC was observed in 13.8% (95% CI: 8.9 to 26.3%) of cases with a higher, but not significantly, rate in AIDS than in HIV-only cases (17.9% versus 9.0%). LGA HC was observed in nine (12.2%, 95% CI: 4.7 to 19.7%) cases, five in AIDS cases. The mean abdominal circumference z/GA score was also slightly reduced with a mean of -0.40 ± 2.03 without significant difference between HIV-only and AIDS cases. A SGA AC was observed in 11 (17.4%, 95% CI: 0 to 40.0%) cases and a LGA AC in five (6.8%, 95% CI: 1.1 to 12.5%) cases. Neither the SGA nor LGA AC proportion differed between AIDS and HIV cases.

**Combining distribution of PTB and growth restriction**. Out of 15 cases of LBW, eight (53.3%) were preterm only, four (26.7%) were SGA only, and three (20.0%) were both PTB and SGA cases. Out of the 63 cases with all four fetal dimensions available, the combined distribution was analyzed by Venn diagram (not shown) and revealed that 24 (38.1%) cases had, at least, one SGA dimension, 11 (17.5%) at least two, 13 (20.6%) only one, seven (11.1%) only two, and two (3.2%) all four SGA fetal dimensions. Out of the 12 SGA BW, 50% were also SGA BL and SGA AC.

DISCUSSION
==========

The HIV-infected women assisted at HUCAM come from the local community, mainly from outside the metropolitan area of the city of Vitória. Due to the study design, case selection was made from a tertiary hospital and there was a strict requirement for ultrasound validated GA estimation, the representativeness of casuistry cannot be assured. A comparison between included and excluded cases regarding the available demographic and clinical details ([Tables 1](#t01){ref-type="table"} and [2](#t02){ref-type="table"}) reveals similarity in maternal age, ethnicity, instruction, parity, previous abortion, AIDS, PTB birth and LBW proportions, but the included cases have significantly more women residing outside the area of the city of Vitória and significantly fewer cases of housewives, unmarried women, alcohol, illegal drug and tobacco users, low antenatal attendance, syphilis in current pregnancy, and cesarean delivery so a selection bias could not be excluded from cases with a lower risk of adverse outcomes. However, HIV-only cases did not differ significantly from AIDS cases regarding any demographics and behavioral and medical characteristics ([Table 2](#t02){ref-type="table"}). Moreover, the demographics and clinical characteristics of the studied cases were similar to other local studies[@B41] and likely represent the poor pregnant women of the large metropolitan areas of Brazil. The fact that 68.9% of the mothers knew their HIV status before pregnancy highlights the need for education in order to minimize the disease\'s burden.

The 17.5% PTB rate observed in this study was higher than that reported for the general population of developed countries (5.0 to 7.0%)[@B35], Brazil (3.4 to 15.0%)[@B51], and the state of Espírito Santo (4.8%)[@B10]. Furthermore, it was similar to the prevalence reported in HIV-infected pregnancies in Europe (14.7 to 16.0%)[@B09] ^,^ [@B53], Africa (13.3 to 21,8%)[@B46] ^,^ [@B54] and Brazil (11.5 to 18.2%)[@B36] ^,^ [@B32], as well as the prevalence reported for the USA (17.0 to 19.9%)[@B49] ^,^ [@B19]. A non-significant trend for a higher proportion of PTB in AIDS cases, compared with HIV-only cases was observed.

In this study, compared to the expected population distribution (10%), the BW z/GA score had a shift towards lower values and the proportion of SGA BW was higher, clearly indicating some fetal growth restriction in the children of HIV-infected women. The results of this investigation are similar to those reported by FAUSTO *et al*. [@B23], in a cohort of 130 full-term infants in Belo Horizonte, state of Minas Gerais: mean BW z/GA score of -0.52 ± 0.88 for the non-infected and -0.83 ± 1.11 for the infected infants, without statistically significant differences between both groups. Although they do not report the SGA proportion, there is a clear shift towards lower values. The finding of an increased proportion of SGA BW in infants of HIV-positive mothers in this investigation accords with previous studies in Africa[@B46] ^,^ [@B54], but was lower than the 31.2% reported by AARON *et al.* in the USA[@B01].

Likewise, the observed 20.2% prevalence of LBW was higher than the 10 to 18% for developed countries[@B19], the 9.0% for population-based Brazilian studies[@B51], and for the 6.6% of SINASC-ES[@B10]. However, it was similar to the reported proportion in Europe[@B09], the USA[@B07], Africa[@B54], and Brazilian HIV-infected women[@B37]. LBW may be due to PTB, SGA or both[@B22]. In developed countries, where LBW rates are low, it is caused mainly by PTB whereas in developing countries, where the prevalence is high, LBW is often due to IUGR[@B06] ^,^ [@B34]. In the casuistry of this study, 26.7% of LBW were due to SGA alone, 53.3% to PTB alone and 20.0% to both PTB and SGA BW. Previous reports of more LBW in AIDS than in non-AIDS cases[@B21] ^,^ [@B36] could not be confirmed.

Little attention has been paid to the temporal and the compartmental frames of fetal growth, that is, the timing at which each fetal organ has its maximum growth and is more vulnerable to growth disturbance. As the various risk factors may act at different moments of intrauterine life they may have different effects on different fetal organs[@B20]. The distribution of SGA affecting fetal compartments other than BW has rarely been reported. The observed proportion of SGA BL in babies born to HIV-infected mothers agrees with some[@B05] ^,^ [@B45] but not all studies[@B29]. HC is an important parameter to assess, because the brain is the last and least affected organ in fetal deprivation[@B15]; a reduced HC was reported in some studies[@B02] ^,^ [@B45], but not confirmed in others[@B29]. Conversely, the AC, reflecting the fetal liver and abdominal subcutaneous mass,[@B16] is the most sensitive and early affected dimension in IUGR; a report of AC analysis in infants of HIV-infected mothers could not be found.

Despite the presence of only 11 (17.5%) cases with at least two concomitant SGA fetal dimensions, it was found that 50% of the 12 cases with SGA BW also have SGA BL or SGA AC, pointing to a split distribution of symmetric and asymmetric types of BW growth restriction. Only one report pointing to an early effect of HIV infection on fetal growth[@B21] could be found.

The relative contribution of HIV and non-HIV-infection risk factors to adverse perinatal outcomes has not been well defined. Maternal poverty, lack of social support, risk behaviors such as tobacco and illegal drug use, medical and gestational diseases such as anemia, diabetes, hypertension, among others, are well-known risk factors for PTB and IUGR in both non-HIV-infected and HIV-infected women[@B18]. Such factors could add to HIV-infection and related conditions (such as high viral load, immunosuppression, HIV-associated infections and ART), increasing the risk of PTB and poor fetal growth. Therefore, it is difficult to separate the independent roles of the non-HIV associated factors from those more directly related to HIV in PTB and IUGR determination[@B08]. In this study, the following tendency was observed: a higher prevalence of PTB, LBW and SGA BW, BL, HC, and AC in infants born to HIV-infected mothers with AIDS compared with those born to non-AIDS mothers. However, due to the small casuistry, it was not possible to explore the role of the severity of HIV infection or its complex interaction with non-HIV comorbidity and specific ART in PTB and fetal growth determination. Larger studies are necessary to solve this issue[@B13].

There are many reasons for the discrepancy in reported HIV-infection related prevalence of PTB and IUGR. Firstly, few studies have used adequate estimates of GA[@B13] ^,^ [@B19] ^,^ [@B44]. A systematic review of Brazilian PTB prevalence found only one out of twelve population-based studies using an early ultrasound validated GA estimate[@B51]. The compliance with that requirement in casuistry of low income publicly assisted women may explain the huge case exclusion in this study.

Secondly, the mean is not an adequate indicator of growth disorders. Besides, comparing the observed mean with a local control group could be misleading because such a control group may not adequately reflect a normal population. However, even without a difference between HIV-exposed and non-exposed fetuses (or in HIV-only versus AIDS cases, as shown in the present study), a significant difference in SGA proportions of growth disturbances could emerge from comparison between the study group and reference distribution, the true \"control group\"[@B14].

Thirdly, the lack of a standardized definition of IUGR[@B13], and the use of a non-representative reference norm[@B07] ^,^ [@B40] ^,^ [@B43] ^,^ [@B55] limit comparability between studies[@B40] ^,^ [@B07]. As the references for birth dimensions underestimate the preterm growth compared with a fetal reference[@B32], a hybrid fetal and neonatal growth curve adjusted to local median term neonatal dimensions should be used[@B07] ^,^ [@B25] ^,^ [@B40]. Furthermore, any available population reference does not account for within-population variations attributable to maternal height, weight, parity and fetal gender, known factors that may affect fetal growth[@B26] ^,^ [@B27] for which the customized or individualized reference has been proposed[@B26] ^,^ [@B27] ^,^ [@B40]. The decision of what reference to adopt affects the growth categorization and the prevalence of growth disorders[@B01]. There is no published growth study either employing that approach in Brazil, or using fetal rather than birth weight reference standard in HIV-infected women.

Lastly, it is difficult to discriminate the role of HIV-infection on fetal growth from the numerous and geographically variable proportion of others risk factors[@B13] ^,^ [@B50]. To add complexity, the association of these risk factors leads to the existence of multiple possible groups, which would demand a larger number of cases to allow a detailed analysis.

**Limitations of this study**. The exclusion of many cases due to missing records and data accounts for an inaccurate representation of the overall local or national HIV-infected mothers. This is a typical issue of the health care contradiction of low-income people in Brazil: regardless of the open access to healthcare and the high proportion of prenatal attendance and hospital delivery, there is evidence of poor quality care[@B42] such as many instances of non-compliance with standard care, lack of access to and delay in delivering complementary exam results. Besides, the poor quality, loss of, and hindrance in accessing patients\' records explain, for instance, the lack of explicit records of cesarean delivery. However, in spite of the huge exclusion, no significant difference regarding PBW or LBW rate was observed.

Due to the small casuistry, a multivariate analysis and adjustment for specific ARV regimen and for important risk factors such as smoking, hypertension and anemia in the PTB and IUGR determination could not be performed. Also, it was not possible to address the potential effects of different ARV schemes in gestation, with or without protease inhibitor (PI), that are not clearly established[@B09] ^,^ [@B19] ^,^ [@B49] ^,^ [@B54]. However, as the majority of patients were already using ARV, the longer exposure to ARV could explain the higher proportion of adverse fetal outcomes in this study.

Finally, a serial fetal growth assessment, as recommended and clinically employed with symphysis-fundal height[@B26] and ultrasound measurements[@B44], was not made. Indeed, a true growth study demands demonstration of a reduced growth velocity along with the gestation. However, the study was limited to a few adequate sets of timely ultrasound measurements of fetal dimensions.

Larger and multicenter natural history studies of HIV-infected cohorts of pregnant women are necessary to provide more definite answers regarding the relationship between HIV infection, co-morbidity, ART use, and preterm birth and fetal growth disorders. Despite the small sample size and these limitations, the authors believe the results of this study are important because of the scarcity of Brazilian reported studies on PTB and IUGR prevalence in HIV-infected women. Moreover, they emphasize the need for prenatal, at birth and postnatal growth monitoring to identify infants with suboptimal growth and to ensure appropriate care and treatment, in order to improve their clinical course, quality of life and prospects.

CONCLUSION
==========

This study found a high prevalence of preterm birth, low birth weight and small gestational age, fetal weight, length, head and abdominal circumferences associated with HIV-infected, ART using, low-income and publicly assisted Brazilian women. A trend for higher prevalence of PTB, LBW and SGA fetal dimensions in infants born to AIDS compared with non-AIDS mothers was observed.
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